Morgan Stanley
EFTR

Morgan Stanley’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Morgan Stanley’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-240
Closed -$70 – 8152
2024
Q2 		$70 Sell
240
-1,375
-85% -$3.26K ﹤0.01% 7421
2024
Q1 		$23.2K Buy
1,615
+175
+12% +$2.09K ﹤0.01% 6442
2023
Q4 		$16.8K Buy
1,440
+643
+81% +$8.62K ﹤0.01% 6708
2023
Q3 		$11.9K Buy
797
+77
+11% +$1.34K ﹤0.01% 6664
2023
Q2 		$14.9K Buy
+720
New +$12.2K ﹤0.01% 6661
2023
Q1 		– Sell
-240
Closed -$2.57K – 7863
2022
Q4 		$2.57K Hold
240
– – ﹤0.01% 7306
2022
Q3 		$3K Sell
240
-50
-17% -$980 ﹤0.01% 7412
2022
Q2 		$10K Buy
290
+288
+14,400% +$17.4K ﹤0.01% 7216
2022
Q1 		$0 Sell
2
-1,145
-100% -$152K ﹤0.01% 8188
2021
Q4 		$237K Buy
1,147
+1,143
+28,575% +$265K ﹤0.01% 5978
2021
Q3 		$1K Sell
4
-20
-83% -$6.45K ﹤0.01% 7822
2021
Q2 		$6K Buy
24
+4
+20% +$984 ﹤0.01% 7357
2021
Q1 		$5K Buy
+20
New +$4.91K ﹤0.01% 7122

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley's EFTR Position: Q3 2024 in Review

Morgan Stanley sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 240 shares — an estimated $70 sold.

Morgan Stanley first reported a position in EFTR in Q1 2021 and held it in 13 quarters. The position peaked at $237K in Q4 2021. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

  • Morgan Stanley reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 240 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $70.
  • Morgan Stanley first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Morgan Stanley's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $237K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.